Researchers at University of California San Diego School of Medicine, with colleagues across the country and around the world, have used whole genome analyses and chemogenetics to identify new drug targets and resistance genes in 262 parasite cell lines of Plasmodium falciparum—protozoan pathogens that cause malaria—that are resistant to 37 diverse antimalarial compounds.